A5068342352- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Hemoglobinopathies and Related Disorders
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Autophagy in Disease and Therapy
- Lymphoma Diagnosis and Treatment
- Immune cells in cancer
- Pneumocystis jirovecii pneumonia detection and treatment
- HER2/EGFR in Cancer Research
- Hematological disorders and diagnostics
- Erythropoietin and Anemia Treatment
- Peptidase Inhibition and Analysis
- Kruppel-like factors research
- PI3K/AKT/mTOR signaling in cancer
- Hematopoietic Stem Cell Transplantation
- Amyloidosis: Diagnosis, Treatment, Outcomes
- HIV/AIDS drug development and treatment
- Blood disorders and treatments
- Peripheral Neuropathies and Disorders
Bicêtre Hospital
2022-2025
Assistance Publique – Hôpitaux de Paris
2006-2025
Université Paris-Saclay
2022-2025
Centre Léon Bérard
2021-2024
Hôpital Paul-Brousse
2019-2024
Inserm
2013-2024
Centre Hospitalier Universitaire de Nice
2012-2021
Institut Bergonié
2016-2021
Hôpital l'Archet
2011-2020
Observatoire de la Côte d’Azur
2020
Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia (CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years. We report the final results of Stop (STIM1) study a long follow-up. Patients and Methods IM was prospectively 100 CML UMRD sustained Molecular recurrence (MR) defined as positivity BCR-ABL transcript quantitative reverse transcriptase polymerase chain reaction assay confirmed by second analysis point that indicated an...
Imatinib (400 mg daily) is considered the best initial therapy for patients with newly diagnosed chronic myeloid leukemia (CML) in phase. However, only a minority of treated imatinib have complete molecular remission.
Despite persistence of leukemic stem cells, patients with chronic myeloid leukemia who achieve and maintain deep molecular responses may successfully stop the tyrosine kinase inhibitor imatinib. However, questions remain unanswered regarding biological basis relapse after imatinib cessation. In IMMUNOSTIM, we monitored 51 from French Stop IMatinib trial for peripheral blood T cells natural killer cells. Molecular relapse-free survival at 24 months was 45.1% (95% CI: 31.44%–58.75%). At time...
BACKGROUND Several studies have demonstrated that approximately one‐half of patients with chronic myeloid leukemia (CML) who receive treatment tyrosine kinase inhibitors (TKIs) and achieve maintain a deep molecular response (DMR) are able to successfully discontinue therapy. In relapse, DMR is rapidly regained upon re‐initiation. METHODS The authors report the results from RE‐STIM, French observational, multicenter study evaluated treatment‐free remission (TFR) in 70 re‐attempted TKI...
Tyrosine kinase inhibitor (TKI) discontinuation is an emerging goal in chronic myelogenous leukemia (CML) management and several studies have demonstrated the feasibility of safely stopping imatinib. A sustained deep molecular response on long-term TKI critical prior to attempting treatment-free remission. Reproducible results from reported recently, failed identify robust reproducible predictive factors for selection best candidates successful cessation.We conducted a prospective national...
Autophagy is induced during differentiation of human monocytes into macrophages that mediated by CSF1/CSF-1/M-CSF (colony stimulating factor 1 [macrophage]). However, little known about the molecular mechanisms link CSF1 receptor engagement to induction autophagy. Here we show CAMKK2-PRKAA1-ULK1 pathway required for CSF1-induced autophagy and monocyte differentiation. We reveal this links P2RY6 autophagy, decipher signaling network P2RY6-mediated In addition, physiological ligand UDP...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. European Stop Kinase Inhibitors (EURO-SKI) study is largest clinical trial investigating cessation of tyrosine...
BACKGROUND We recently reported that peroxisome proliferator‐activated receptor γ agonists target chronic myeloid leukemia (CML) quiescent stem cells in vitro by decreasing transcription of STAT5 . Here the ACTIM phase 2 clinical trial, we asked whether pioglitazone add‐on therapy to imatinib would impact CML residual disease, as assessed BCR‐ABL1 transcript quantification. METHODS patients were eligible if treated with for at least years a stable daily dose, having yielded major molecular...
Summary Myeloproliferative neoplasm‐related myelofibrosis is associated with cytopenic or proliferative phases, splenomegaly and constitutional symptoms. Few effective treatments are available small series suggested that interferon could be an option for therapy. We performed a retrospective study of pegylated‐interferon α‐2a (Peg‐ IFN α‐2a) therapy in myelofibrosis. Sixty‐two patients treated Peg‐ at 17 French Belgian centres were included. Responses determined based on the criteria...
BACKGROUND The ultimate goal of chronic myeloid leukemia management in the tyrosine kinase inhibitor (TKI) era for patients who obtain deep molecular responses is maintaining a durable off‐treatment response after treatment discontinuation; this situation called treatment‐free remission (TFR). Knowledge accumulated during last 10 years justifies moving TFR strategies from research to clinical practice. METHODS Twenty experts French Chronic Myeloid Leukemia Study Group (France Intergroupe des...
During the last decade, use of tyrosine kinase inhibitor (TKI) therapy has modified natural history chronic myeloid leukemia (CML) allowing an increase overall and disease-free survival, especially in patients whom molecular residual disease becomes undetectable. However, it been demonstrated that BCR-ABL1- expressing leukemic stem cells (LSCs) persist deep response. It also shown discontinuation Imatinib leads to a relapse majority cases. To determine possible relationship between these two...
Abstract Myeloproliferative neoplasms (MPNs) are uncommon in children/young adults. Here, we present data on unselected patients diagnosed before 25 years of age included from 38 centers 15 countries. Sequential were included. We identified 444 patients, with median follow-up 9.7 (0-47.8). Forty-nine (11.1%) had a history thrombosis at diagnosis, 49 new thrombotic events recorded (1.16% patient per year [pt/y]), perihepatic vein thromboses most frequent (47.6% venous events), and logistic...
Imatinib has emerged as the lead compound for clinical development against chronic myelogenous leukemia (CML). induces apoptosis of CML cells, but how drug kills them is only partially understood. This study was conducted to 1) analyze effect imatinib on and differentiation Bcr-Abl-positive K562 cell line 2) determine influence that have each other in this appropriate model. A 36 h exposure cells 1 µM induced DNA fragmentation (Fig. 1A), indicating underwent an apoptotic program presence...
An open-label, phase II non-randomised trial was conducted with darbepoetin (DAR), an erythropoiesis-stimulating factor prolonged half-life, at a weekly dose of 300 mug subcutaneously in 62 anaemic patients myelodysplastic syndrome (MDS) endogenous erythropoietin (EPO) level <500 mU/ml. Most the were classified as low or intermediate 1 according to International Prognostic Scoring System. After 12 weeks, 44 (71%) had erythroid response (34 major and 10 minor), including eight 13 who previous...